Targeting  	Targeting  	 VBG	O
innate  	innate  	 JJ	O
immune  	immune  	 JJ	O
pathways  	pathways  	 NN	O
in  	in  	 IN	O
cancer  	cancer  	 NN	B-NP
immunotherapy 	immunotherapy 	 NNS	I-NP
:  	:  	 :	O
state  	state  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
art  	art  	 NN	O
Complement-based  	Complement-based  	 JJ	O
cancer  	cancer  	 NN	B-NP
immunotherapy  	immunotherapy  	 NN	I-NP
is  	is  	 VBZ	O
gaining  	gaining  	 VBG	B-NP
momentum  	momentum  	 NN	I-NP
in  	in  	 IN	O
recent  	recent  	 JJ	O
years  	years  	 NNS	O
due  	due  	 JJ	O
to  	to  	 TO	O
the  	the  	 DT	O
growing  	growing  	 VBG	O
number  	number  	 NN	O
of  	of  	 IN	O
therapeutic  	therapeutic  	 JJ	B-NP
anti-tumor  	anti-tumor  	 JJ	I-NP
antibodies  	antibodies  	 NNS	I-NP
that  	that  	 WDT	O
are  	are  	 VBP	O
receiving  	receiving  	 VBG	B-NP
approval  	approval  	 NN	I-NP
for  	for  	 IN	I-NP
clinical  	clinical  	 JJ	I-NP
trials  	trials  	 NNS	I-NP
and  	and  	 CC	O
are  	are  	 VBP	O
currently  	currently  	 RB	O
used  	used  	 VBN	O
in  	in  	 IN	O
clinical  	clinical  	 JJ	B-NP
cancer  	cancer  	 NN	I-NP
care 	care 	 NN	I-NP
.  	.  	 .	O
Even  	Even  	 RB	O
though  	though  	 IN	O
some  	some  	 DT	O
anti-tumor  	anti-tumor  	 JJ	B-NP
antibodies  	antibodies  	 NNS	I-NP
have  	have  	 VBP	O
shown  	shown  	 VBN	O
moderate  	moderate  	 JJ	O
therapeutic  	therapeutic  	 JJ	B-NP
efficacy 	efficacy 	 NN	I-NP
,  	,  	 ,	O
most  	most  	 JJS	O
of  	of  	 IN	O
them  	them  	 PRP	O
still  	still  	 RB	O
lag  	lag  	 VBP	O
behind 	behind 	 RB	O
,  	,  	 ,	O
having  	having  	 VBG	O
failed  	failed  	 VBN	O
to  	to  	 TO	O
produce  	produce  	 VB	O
adequately  	adequately  	 RB	O
effective  	effective  	 JJ	O
responses 	responses 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
urging  	urging  	 VBG	B-NP
need  	need  	 NN	I-NP
for  	for  	 IN	I-NP
a  	a  	 DT	I-NP
therapeutic  	therapeutic  	 JJ	I-NP
platform  	platform  	 NN	I-NP
that  	that  	 WDT	O
will  	will  	 MD	O
enhance  	enhance  	 VB	O
both  	both  	 PDT	O
the  	the  	 DT	O
humoral  	humoral  	 NN	B-NP
and  	and  	 CC	O
cellular  	cellular  	 JJ	B-NP
effects  	effects  	 NNS	I-NP
of  	of  	 IN	I-NP
antibody  	antibody  	 NN	I-NP
treatment  	treatment  	 NN	I-NP
prompts  	prompts  	 VBZ	O
the  	the  	 DT	O
design  	design  	 NN	O
of  	of  	 IN	O
more  	more  	 RBR	O
effective  	effective  	 JJ	O
combinatorial  	combinatorial  	 JJ	B-NP
therapeutics  	therapeutics  	 NN	I-NP
for  	for  	 IN	O
enhancing  	enhancing  	 VBG	O
complement-mediated  	complement-mediated  	 JJ	O
tumor  	tumor  	 NN	B-NP
cytotoxicity  	cytotoxicity  	 NN	I-NP
in  	in  	 IN	O
cancer  	cancer  	 NN	B-NP
patients 	patients 	 NNS	I-NP
.  	.  	 .	O
Cancer  	Cancer  	 NN	B-NP
cells  	cells  	 NNS	I-NP
express  	express  	 VBP	O
or  	or  	 CC	O
sequester  	sequester  	 JJ	O
host  	host  	 NN	B-NP
membrane-bound  	membrane-bound  	 NN	I-NP
and  	and  	 CC	O
fluid-phase  	fluid-phase  	 JJ	B-NP
complement  	complement  	 JJ	I-NP
regulators  	regulators  	 NNS	I-NP
in  	in  	 IN	O
order  	order  	 NN	O
to  	to  	 TO	O
evade  	evade  	 VB	O
complement  	complement  	 JJ	B-NP
attack  	attack  	 NN	I-NP
and  	and  	 CC	O
establish  	establish  	 VB	O
an  	an  	 DT	O
immunosuppressive  	immunosuppressive  	 JJ	B-NP
microenvironment  	microenvironment  	 NN	I-NP
for  	for  	 IN	I-NP
tumor  	tumor  	 NN	I-NP
growth 	growth 	 NN	I-NP
.  	.  	 .	O
Moreover 	Moreover 	 RB	O
,  	,  	 ,	O
membrane  	membrane  	 JJ	B-NP
complement  	complement  	 JJ	I-NP
regulators  	regulators  	 NNS	I-NP
appear  	appear  	 VBP	O
to  	to  	 TO	O
modulate  	modulate  	 VB	O
several  	several  	 JJ	O
aspects  	aspects  	 NNS	O
of  	of  	 IN	O
T-cell  	T-cell  	 JJ	B-NP
immunity  	immunity  	 NN	I-NP
that  	that  	 WDT	O
are  	are  	 VBP	O
relevant  	relevant  	 JJ	O
to  	to  	 TO	O
the  	the  	 DT	O
anti-tumor 	anti-tumor 	 JJ	B-NP
,  	,  	 ,	O
adaptive  	adaptive  	 JJ	B-NP
T-cell  	T-cell  	 JJ	I-NP
response 	response 	 NN	I-NP
.  	.  	 .	O
Recently 	Recently 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
concept  	concept  	 NN	O
that  	that  	 IN	O
complement  	complement  	 JJ	B-NP
activation  	activation  	 NN	I-NP
is  	is  	 VBZ	O
unfavorable  	unfavorable  	 JJ	O
for  	for  	 IN	O
tumor  	tumor  	 NN	B-NP
growth  	growth  	 NN	I-NP
has  	has  	 VBZ	O
been  	been  	 VBN	O
drastically  	drastically  	 RB	O
challenged  	challenged  	 VBN	O
by  	by  	 IN	O
evidence  	evidence  	 NN	O
that  	that  	 IN	O
points  	points  	 NNS	O
to  	to  	 TO	O
a  	a  	 DT	O
novel  	novel  	 NN	B-NP
immunomodulatory  	immunomodulatory  	 NN	I-NP
role  	role  	 NN	I-NP
of  	of  	 IN	I-NP
complement  	complement  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
tumor  	tumor  	 NN	B-NP
microenvironment 	microenvironment 	 NN	I-NP
.  	.  	 .	O
Taken  	Taken  	 VBN	O
together 	together 	 RB	O
,  	,  	 ,	O
these  	these  	 DT	O
findings  	findings  	 NNS	O
form  	form  	 VBP	O
a  	a  	 DT	O
new  	new  	 JJ	O
conceptual  	conceptual  	 JJ	B-NP
framework  	framework  	 NN	I-NP
that  	that  	 IN	O
integrates  	integrates  	 JJ	O
innate  	innate  	 JJ	O
immunity  	immunity  	 NN	O
to  	to  	 TO	O
cancer  	cancer  	 NN	B-NP
development 	development 	 NN	I-NP
.  	.  	 .	O
Furthermore 	Furthermore 	 RB	O
,  	,  	 ,	O
they  	they  	 PRP	O
are  	are  	 VBP	O
anticipated  	anticipated  	 VBN	O
to  	to  	 TO	O
lead  	lead  	 VB	O
to  	to  	 TO	O
the  	the  	 DT	O
rational  	rational  	 JJ	O
design  	design  	 NN	O
of  	of  	 IN	O
strategies  	strategies  	 NNS	O
that  	that  	 WDT	O
will  	will  	 MD	O
exploit  	exploit  	 VB	O
innate  	innate  	 JJ	O
immune  	immune  	 JJ	O
systems 	systems 	 NNS	O
,  	,  	 ,	O
such  	such  	 JJ	O
as  	as  	 IN	O
complement 	complement 	 NN	B-NP
,  	,  	 ,	O
in  	in  	 IN	O
a  	a  	 DT	O
patient-oriented 	patient-oriented 	 JJ	O
,  	,  	 ,	O
individualized  	individualized  	 JJ	O
manner  	manner  	 NN	O
for  	for  	 IN	O
effective  	effective  	 JJ	O
cancer  	cancer  	 NN	B-NP
immunotherapy 	immunotherapy 	 NN	I-NP
.  	.  	 .	O
